Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964184003> ?p ?o ?g. }
- W2964184003 endingPage "566" @default.
- W2964184003 startingPage "559" @default.
- W2964184003 abstract "PurposePain response rates are equivalent after single 8 Gy and fractionated palliative radiation therapy for bone metastases. Reirradiation remains more frequent after a single fraction, although this does not simply reflect pain recurrence. Given the possible role of stereotactic radiation therapy in providing durable pain control, measures of durability are required. Net pain relief (NPR), the proportion of remaining life spent with pain response, may provide this. This study assesses the use of NPR as an outcome measure after palliative radiation therapy for bone metastases.Methods and MaterialsThis is a secondary analysis of data collected in the Dutch Bone Metastasis Study, a randomized trial comparing palliative radiation therapy delivered as 8 Gy in a single fraction and 24 Gy in 6 fractions. NPR was assessed by survival cohorts, treatment regimen, and primary diagnoses. The consequences of missing data upon the use of NPR in future studies were considered within sensitivity analyses.ResultsPatients whose pain improved after palliative radiation therapy experienced improvement for 56.6% of their remaining lives. Missing responses in questionnaires mean the range of uncertainty in NPR is 36.1% to 62.1%. When response beyond reirradiation was excluded, NPR after treatments of single-fraction 8 Gy and 24 Gy in 6 fractions was 49.0% and 56.5%, respectively (P = .004). Differential willingness to reirradiate may be influencing this outcome. When response beyond reirradiation was included, this difference was not seen (NPR of 55.4% vs 57.7%, respectively [P = .191]).ConclusionsPatients who responded to conventional radiation therapy experienced improved pain control for approximately half of their remaining life. NPR may provide valuable information in assessing pain response durability. Missing data are, however, inevitable in this population. This must be minimized and the consequences recognized and reported. Additionally, reirradiation protocols and the frequency and duration of trial follow-up may have a significant impact upon this outcome, requiring careful consideration during trial design if NPR is to be used in future studies. Pain response rates are equivalent after single 8 Gy and fractionated palliative radiation therapy for bone metastases. Reirradiation remains more frequent after a single fraction, although this does not simply reflect pain recurrence. Given the possible role of stereotactic radiation therapy in providing durable pain control, measures of durability are required. Net pain relief (NPR), the proportion of remaining life spent with pain response, may provide this. This study assesses the use of NPR as an outcome measure after palliative radiation therapy for bone metastases. This is a secondary analysis of data collected in the Dutch Bone Metastasis Study, a randomized trial comparing palliative radiation therapy delivered as 8 Gy in a single fraction and 24 Gy in 6 fractions. NPR was assessed by survival cohorts, treatment regimen, and primary diagnoses. The consequences of missing data upon the use of NPR in future studies were considered within sensitivity analyses. Patients whose pain improved after palliative radiation therapy experienced improvement for 56.6% of their remaining lives. Missing responses in questionnaires mean the range of uncertainty in NPR is 36.1% to 62.1%. When response beyond reirradiation was excluded, NPR after treatments of single-fraction 8 Gy and 24 Gy in 6 fractions was 49.0% and 56.5%, respectively (P = .004). Differential willingness to reirradiate may be influencing this outcome. When response beyond reirradiation was included, this difference was not seen (NPR of 55.4% vs 57.7%, respectively [P = .191]). Patients who responded to conventional radiation therapy experienced improved pain control for approximately half of their remaining life. NPR may provide valuable information in assessing pain response durability. Missing data are, however, inevitable in this population. This must be minimized and the consequences recognized and reported. Additionally, reirradiation protocols and the frequency and duration of trial follow-up may have a significant impact upon this outcome, requiring careful consideration during trial design if NPR is to be used in future studies." @default.
- W2964184003 created "2019-07-30" @default.
- W2964184003 creator A5010993780 @default.
- W2964184003 creator A5014743334 @default.
- W2964184003 creator A5041065594 @default.
- W2964184003 creator A5048377574 @default.
- W2964184003 creator A5073760994 @default.
- W2964184003 creator A5089586523 @default.
- W2964184003 date "2019-11-01" @default.
- W2964184003 modified "2023-10-11" @default.
- W2964184003 title "Net Pain Relief After Palliative Radiation Therapy for Painful Bone Metastases: A Useful Measure to Reflect Response Duration? A Further Analysis of the Dutch Bone Metastasis Study" @default.
- W2964184003 cites W1540052950 @default.
- W2964184003 cites W1678814182 @default.
- W2964184003 cites W1878601112 @default.
- W2964184003 cites W1917305370 @default.
- W2964184003 cites W1977291071 @default.
- W2964184003 cites W1995975133 @default.
- W2964184003 cites W2004800876 @default.
- W2964184003 cites W2023085317 @default.
- W2964184003 cites W2028920210 @default.
- W2964184003 cites W2033981686 @default.
- W2964184003 cites W2042823833 @default.
- W2964184003 cites W2053787128 @default.
- W2964184003 cites W2084061645 @default.
- W2964184003 cites W2084874632 @default.
- W2964184003 cites W2090537656 @default.
- W2964184003 cites W2093640728 @default.
- W2964184003 cites W2108145085 @default.
- W2964184003 cites W2112973818 @default.
- W2964184003 cites W2119941303 @default.
- W2964184003 cites W2138156952 @default.
- W2964184003 cites W2139879375 @default.
- W2964184003 cites W2165747307 @default.
- W2964184003 cites W2195040438 @default.
- W2964184003 cites W2247396128 @default.
- W2964184003 cites W2255846762 @default.
- W2964184003 cites W2343789768 @default.
- W2964184003 cites W2549509746 @default.
- W2964184003 cites W2616561001 @default.
- W2964184003 cites W2790983120 @default.
- W2964184003 doi "https://doi.org/10.1016/j.ijrobp.2019.07.009" @default.
- W2964184003 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6859481" @default.
- W2964184003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31344434" @default.
- W2964184003 hasPublicationYear "2019" @default.
- W2964184003 type Work @default.
- W2964184003 sameAs 2964184003 @default.
- W2964184003 citedByCount "10" @default.
- W2964184003 countsByYear W29641840032020 @default.
- W2964184003 countsByYear W29641840032021 @default.
- W2964184003 countsByYear W29641840032022 @default.
- W2964184003 countsByYear W29641840032023 @default.
- W2964184003 crossrefType "journal-article" @default.
- W2964184003 hasAuthorship W2964184003A5010993780 @default.
- W2964184003 hasAuthorship W2964184003A5014743334 @default.
- W2964184003 hasAuthorship W2964184003A5041065594 @default.
- W2964184003 hasAuthorship W2964184003A5048377574 @default.
- W2964184003 hasAuthorship W2964184003A5073760994 @default.
- W2964184003 hasAuthorship W2964184003A5089586523 @default.
- W2964184003 hasBestOaLocation W29641840031 @default.
- W2964184003 hasConcept C121608353 @default.
- W2964184003 hasConcept C126322002 @default.
- W2964184003 hasConcept C141071460 @default.
- W2964184003 hasConcept C159110408 @default.
- W2964184003 hasConcept C168563851 @default.
- W2964184003 hasConcept C2777783956 @default.
- W2964184003 hasConcept C2779013556 @default.
- W2964184003 hasConcept C2781413609 @default.
- W2964184003 hasConcept C2989005 @default.
- W2964184003 hasConcept C2993247534 @default.
- W2964184003 hasConcept C2994186709 @default.
- W2964184003 hasConcept C509974204 @default.
- W2964184003 hasConcept C71924100 @default.
- W2964184003 hasConceptScore W2964184003C121608353 @default.
- W2964184003 hasConceptScore W2964184003C126322002 @default.
- W2964184003 hasConceptScore W2964184003C141071460 @default.
- W2964184003 hasConceptScore W2964184003C159110408 @default.
- W2964184003 hasConceptScore W2964184003C168563851 @default.
- W2964184003 hasConceptScore W2964184003C2777783956 @default.
- W2964184003 hasConceptScore W2964184003C2779013556 @default.
- W2964184003 hasConceptScore W2964184003C2781413609 @default.
- W2964184003 hasConceptScore W2964184003C2989005 @default.
- W2964184003 hasConceptScore W2964184003C2993247534 @default.
- W2964184003 hasConceptScore W2964184003C2994186709 @default.
- W2964184003 hasConceptScore W2964184003C509974204 @default.
- W2964184003 hasConceptScore W2964184003C71924100 @default.
- W2964184003 hasFunder F4320307778 @default.
- W2964184003 hasFunder F4320307779 @default.
- W2964184003 hasFunder F4320311542 @default.
- W2964184003 hasFunder F4320312699 @default.
- W2964184003 hasFunder F4320319985 @default.
- W2964184003 hasFunder F4320319990 @default.
- W2964184003 hasFunder F4320322148 @default.
- W2964184003 hasFunder F4320332193 @default.
- W2964184003 hasFunder F4320334626 @default.
- W2964184003 hasIssue "3" @default.
- W2964184003 hasLocation W29641840031 @default.
- W2964184003 hasLocation W29641840032 @default.
- W2964184003 hasLocation W29641840033 @default.